1
|
Estévez MÁ, Lanio N, Molina Á, Jiménez-León MR, Picado MJ, Esteban E, Sánchez S, Pallarés L, Julià MR. Extra-criteria antiphospholipid antibodies in patients with small vessel brain lesions and clinical manifestations associated with antiphospholipid syndrome. J Stroke Cerebrovasc Dis 2023; 32:107034. [PMID: 36842350 DOI: 10.1016/j.jstrokecerebrovasdis.2023.107034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2022] [Revised: 01/24/2023] [Accepted: 01/25/2023] [Indexed: 02/27/2023] Open
Abstract
OBJECTIVES Neurological manifestations compatible with small vessel brain lesions (SVBL), such as migraine, cognitive impairment, seizures, and transverse myelitis, may be related to antiphospholipid syndrome (APS) and patients could need APS therapies even though they do not fit into thrombosis or obstetric morbidity. Furthermore, extra-criteria antiphospholipid antibodies (aPL) provide an increase in sensitivity in patients with clinical manifestations related to APS but negative for IgG/IgM anticardiolipin (aCL), anti-β2 glycoprotein I (aβ2GPI), and lupus anticoagulant, which are the antibodies included in the classification criteria for APS. METHODS We determined extra-criteria aPL in 65 SVBL patients with neurological traits and Magnetic Resonance Imaging suggestive of APS but negative for APS classification criteria, 47 of whom were prospectively followed and tested over three years. A group of 95 patients with autoimmune diseases (AD) but without clinical traits of APS was also studied. RESULTS A persistent presence of extra-criteria aPL was detected in 27.7% of patients: 12.77% IgM anti- prothrombin (PT), 6.38% IgG anti-PT, 6.38% IgM anti-phosphatidylethanolamine (PE), 4.26% IgA aβ2GPI, 2.13% IgG anti-phosphatidylserine/prothrombin (PS/PT) and 2.13% IgM anti-PS/PT. There was a tendency towards a higher prevalence of these aPL in SVBL patients than in AD - especially for IgA aβ2GPI - and a lack of IgG aPS/PT positivity in the AD group. We found no SVBL patient positive for IgA aCL, IgG anti-PE, annexin V, or aβ2GPI domain I. CONCLUSIONS Extra-criteria aPL can improve sensitivity for APS diagnosis in patients with SVBL, especially IgA aβ2GPI and IgG anti-PS/PT antibodies.
Collapse
Affiliation(s)
- Miguel Ángel Estévez
- Immunology Department, Hospital Universitari Son Espases, Institut d'Investigació Sanitària Illes Balears (IdISBa), 07010, Palma de Mallorca, Balearic Islands, Spain
| | - Nallibe Lanio
- Immunology Department, Hospital Universitari Son Espases, Institut d'Investigació Sanitària Illes Balears (IdISBa), 07010, Palma de Mallorca, Balearic Islands, Spain
| | - Águeda Molina
- Immunology Department, Hospital Universitari Son Espases, Institut d'Investigació Sanitària Illes Balears (IdISBa), 07010, Palma de Mallorca, Balearic Islands, Spain
| | - Maria Reyes Jiménez-León
- Immunology Department, Hospital Universitari Son Espases, Institut d'Investigació Sanitària Illes Balears (IdISBa), 07010, Palma de Mallorca, Balearic Islands, Spain
| | - María José Picado
- Radiology Department, Hospital Universitari Son Espases, Institut d'Investigació Sanitària Illes Balears (IdISBa), 07010, Palma de Mallorca, Balearic Islands, Spain
| | - Eva Esteban
- Systemic Autoimmune Diseases Unit, Hospital Universitari Son Espases, Institut d'Investigació Sanitària Illes Balears (IdISBa), 07010, Palma de Mallorca, Balearic Islands, Spain
| | - Sonia Sánchez
- Systemic Autoimmune Diseases Unit, Hospital Fundación Alcorcón, Madrid, Spain
| | - Lucio Pallarés
- Systemic Autoimmune Diseases Unit, Hospital Universitari Son Espases, Institut d'Investigació Sanitària Illes Balears (IdISBa), 07010, Palma de Mallorca, Balearic Islands, Spain
| | - Maria Rosa Julià
- Immunology Department, Hospital Universitari Son Espases, Institut d'Investigació Sanitària Illes Balears (IdISBa), 07010, Palma de Mallorca, Balearic Islands, Spain.
| |
Collapse
|
2
|
Thiel J, Koppolu R, Trautewig C, Hertig C, Kale SM, Erbe S, Mascher M, Himmelbach A, Rutten T, Esteban E, Pasha A, Kumlehn J, Provart NJ, Vanderauwera S, Frohberg C, Schnurbusch T. Transcriptional landscapes of floral meristems in barley. Sci Adv 2021; 7:eabf0832. [PMID: 33910893 PMCID: PMC8081368 DOI: 10.1126/sciadv.abf0832] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Accepted: 02/26/2021] [Indexed: 05/02/2023]
Abstract
Organ development in plants predominantly occurs postembryonically through combinatorial activity of meristems; therefore, meristem and organ fate are intimately connected. Inflorescence morphogenesis in grasses (Poaceae) is complex and relies on a specialized floral meristem, called spikelet meristem, that gives rise to all other floral organs and ultimately the grain. The fate of the spikelet determines reproductive success and contributes toward yield-related traits in cereal crops. Here, we examined the transcriptional landscapes of floral meristems in the temperate crop barley (Hordeum vulgare L.) using RNA-seq of laser capture microdissected tissues from immature, developing floral structures. Our unbiased, high-resolution approach revealed fundamental regulatory networks, previously unknown pathways, and key regulators of barley floral fate and will equally be indispensable for comparative transcriptional studies of grass meristems.
Collapse
Affiliation(s)
- J Thiel
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstr. 3, OT Gatersleben, 06466 Seeland, Germany.
| | - R Koppolu
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstr. 3, OT Gatersleben, 06466 Seeland, Germany.
| | - C Trautewig
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstr. 3, OT Gatersleben, 06466 Seeland, Germany
| | - C Hertig
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstr. 3, OT Gatersleben, 06466 Seeland, Germany
| | - S M Kale
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstr. 3, OT Gatersleben, 06466 Seeland, Germany
| | - S Erbe
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstr. 3, OT Gatersleben, 06466 Seeland, Germany
| | - M Mascher
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstr. 3, OT Gatersleben, 06466 Seeland, Germany
| | - A Himmelbach
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstr. 3, OT Gatersleben, 06466 Seeland, Germany
| | - T Rutten
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstr. 3, OT Gatersleben, 06466 Seeland, Germany
| | - E Esteban
- Department of Cell and Systems Biology/Centre for the Analysis of Genome Evolution and Function, University of Toronto, 25 Willcocks St., Toronto, ON M5S 3B2, Canada
| | - A Pasha
- Department of Cell and Systems Biology/Centre for the Analysis of Genome Evolution and Function, University of Toronto, 25 Willcocks St., Toronto, ON M5S 3B2, Canada
| | - J Kumlehn
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstr. 3, OT Gatersleben, 06466 Seeland, Germany
| | - N J Provart
- Department of Cell and Systems Biology/Centre for the Analysis of Genome Evolution and Function, University of Toronto, 25 Willcocks St., Toronto, ON M5S 3B2, Canada
| | - S Vanderauwera
- BASF Belgium Coordination Center CommV, Innovation Center Gent, Technologiepark-Zwijnaarde 101, 9052 Gent, Belgium
| | - C Frohberg
- BASF Belgium Coordination Center CommV, Innovation Center Gent, Technologiepark-Zwijnaarde 101, 9052 Gent, Belgium
| | - T Schnurbusch
- Leibniz Institute of Plant Genetics and Crop Plant Research (IPK), Corrensstr. 3, OT Gatersleben, 06466 Seeland, Germany.
- Martin Luther University Halle-Wittenberg, Faculty of Natural Sciences III, Institute of Agricultural and Nutritional Sciences, 06120 Halle, Germany
| |
Collapse
|
3
|
Gray J, Rodríguez-Abreu D, Powell S, Hochmair M, Gadgeel S, Esteban E, Felip E, Speranza G, De Angelis F, Dómine M, Cheng S, Bischoff H, Peled N, Reck M, Hui R, Garon E, Boyer M, Kurata T, Yang J, Jensen E, Souza F, Garassino M. FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.141] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
4
|
Niedermeier C, Barrera A, Esteban E, Ivandic I, Sabariego C. The Impact of the Change in Payment System for German Psychiatric
Clinics on Treatment Success: An Interrupted Time Series
Analysis. Gesundheitswesen 2020; 82:559-567. [DOI: 10.1055/a-0828-7504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Abstract
Background In Germany a new reimbursement system for psychiatric
clinics was proposed in 2009 based on the § 17d KHG
Psych-Entgeltsystem. The system can be voluntary implemented by clinics
since 2013 but therapists are frequently afraid it might affect treatment
negatively.
Objectives To evaluate whether the new system has a negative impact
on treatment success by analysing routinely collected data in a Bavarian
clinic.
Material and methods Aggregated data of 1760 patients treated in the
years 2007–2016 was analysed with segmented regression analysis of
interrupted time series to assess the effects of the system on treatment
success, operationalized with three outcome variables. A negative change in
level after a lag period was hypothesized. The robustness of results was
tested by sensitivity analyses.
Results The percentage of patients with treatment success tends to
increase after the new system but no significant change in level was
observed. The sensitivity analyses corroborate results for 2 outcomes but
when the intervention point was shifted, the positive change in level for
the third outcome became significant.
Conclusions Our initial hypothesis is not supported. However, the
sensitivity analyses disclosed uncertainties and our study has limitations,
such as a short observation time post intervention. Results are not
generalizable as data of a single clinic was analysed. Nevertheless, we show
the importance of collecting and analysing routine data to assess the impact
of policy changes on patient outcomes.
Collapse
Affiliation(s)
- Christina Niedermeier
- Institut für Medizinische Informationsverarbeitung Biometrie
und Epidemiologie (IBE), Lehrstuhl für Public Health und
Versorgungsforschung, München
| | - Andrea Barrera
- Dynamisch-Psychiatrische Klinik Menterschwaige, Klinik für
stationäre Psychiatrie, Psychotherapie, Psychosomatik und Psychoanalyse,
München
| | - Eva Esteban
- Institut für Medizinische Informationsverarbeitung Biometrie
und Epidemiologie (IBE), Lehrstuhl für Public Health und
Versorgungsforschung, München
| | - Ivana Ivandic
- Institut für Medizinische Informationsverarbeitung Biometrie
und Epidemiologie (IBE), Lehrstuhl für Public Health und
Versorgungsforschung, München
| | - Carla Sabariego
- Institut für Medizinische Informationsverarbeitung Biometrie
und Epidemiologie (IBE), Lehrstuhl für Public Health und
Versorgungsforschung, München
| |
Collapse
|
5
|
Sroczynski G, Esteban E, Widschwendter A, Oberaigner W, Borena W, von Laer D, Hackl M, Endel G, Siebert U. Reducing overtreatment associated with overdiagnosis in cervical cancer screening-A model-based benefit-harm analysis for Austria. Int J Cancer 2020; 147:1131-1142. [PMID: 31872420 DOI: 10.1002/ijc.32849] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2019] [Revised: 11/26/2019] [Accepted: 12/12/2019] [Indexed: 12/24/2022]
Abstract
A general concern exists that cervical cancer screening using human papillomavirus (HPV) testing may lead to considerable overtreatment. We evaluated the trade-off between benefits and overtreatment among different screening strategies differing by primary tests (cytology, p16/Ki-67, HPV alone or in combinations), interval, age and diagnostic follow-up algorithms. A Markov state-transition model calibrated to the Austrian epidemiological context was used to predict cervical cancer cases, deaths, overtreatments and incremental harm-benefit ratios (IHBR) for each strategy. When considering the same screening interval, HPV-based screening strategies were more effective compared to cytology or p16/Ki-67 testing (e.g., relative reduction in cervical cancer with biennial screening: 67.7% for HPV + Pap cotesting, 57.3% for cytology and 65.5% for p16/Ki-67), but were associated with increased overtreatment (e.g., 19.8% more conizations with biennial HPV + Papcotesting vs. biennial cytology). The IHBRs measured in unnecessary conizations per additional prevented cancer-related death were 31 (quinquennial Pap + p16/Ki-67-triage), 49 (triennial Pap + p16/Ki-67-triage), 58 (triennial HPV + Pap cotesting), 66 (biennial HPV + Pap cotesting), 189 (annual Pap + p16/Ki-67-triage) and 401 (annual p16/Ki-67 testing alone). The IHBRs increased significantly with increasing screening adherence rates and slightly with lower age at screening initiation, with a reduction in HPV incidence or with lower Pap-test sensitivity. Depending on the accepted IHBR threshold, biennial or triennial HPV-based screening in women as of age 30 and biennial cytology in younger women may be considered in opportunistic screening settings with low or moderate adherence such as in Austria. In organized settings with high screening adherence and in postvaccination settings with lower HPV prevalence, the interval may be prolonged.
Collapse
Affiliation(s)
- Gaby Sroczynski
- Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria.,Division of Health Technology Assessment and Bioinformatics, ONCOTYROL - Center for Personalized Cancer Medicine, Innsbruck, Austria
| | - Eva Esteban
- Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria.,Division of Health Technology Assessment and Bioinformatics, ONCOTYROL - Center for Personalized Cancer Medicine, Innsbruck, Austria
| | - Andreas Widschwendter
- Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria
| | - Wilhelm Oberaigner
- Institute for Clinical Epidemiology, Cancer Registry Tyrol, Tirol Kliniken, Innsbruck, Austria
| | - Wegene Borena
- Division of Virology, Department of Hygiene, Microbiology, Social Medicine, Medical University of Innsbruck, Innsbruck, Austria
| | - Dorothee von Laer
- Division of Virology, Department of Hygiene, Microbiology, Social Medicine, Medical University of Innsbruck, Innsbruck, Austria
| | - Monika Hackl
- Statistics Austria, Austrian National Cancer Registry, Vienna, Austria
| | - Gottfried Endel
- Department for Evidence-Based Economic Health Care, Main Association of Austrian Social Insurance Institutions, Vienna, Austria
| | - Uwe Siebert
- Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria.,Division of Health Technology Assessment and Bioinformatics, ONCOTYROL - Center for Personalized Cancer Medicine, Innsbruck, Austria.,Center for Health Decision Science, Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA.,Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
| |
Collapse
|
6
|
Guitart C, Alejandre C, Torrús I, Balaguer M, Esteban E, Cambra FJ, Jordan I. Impact of a modification of the clinical practice guide of the American Academy of Pediatrics in the management of severe acute bronchiolitis in a pediatric intensive care unit. Med Intensiva 2019; 45:289-297. [PMID: 31892419 PMCID: PMC7115415 DOI: 10.1016/j.medin.2019.10.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2019] [Revised: 10/24/2019] [Accepted: 10/29/2019] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To describe the characteristics and evolution of patients with bronchiolitis admitted to a pediatric intensive care unit, and compare treatment pre- and post-publication of the American Academy of Pediatrics clinical practice guide. DESIGN A descriptive and observational study was carried out between September 2010 and September 2017. SETTING Pediatric intensive care unit. PATIENTS Infants under one year of age with severe bronchiolitis. INTERVENTIONS Two periods were compared (2010-14 and 2015-17), corresponding to before and after modification of the American Academy of Pediatrics guidelines for the management of bronchiolitis in hospital. MAIN VARIABLES Patient sex, age, comorbidities, severity, etiology, administered treatment, bacterial infections, respiratory and inotropic support, length of stay and mortality. RESULTS A total of 706 patients were enrolled, of which 414 (58.6%) males, with a median age of 47 days (IQR 25-100.25). Median bronchiolitis severity score (BROSJOD) upon admission: 9 points (IQR 7-11). Respiratory syncytial virus appeared in 460 (65.16%) patients. The first period (2010-14) included 340 patients and the second period (2015-17) 366 patients. More adrenalin and hypertonic saline nebulizations and more corticosteroid treatment were administered in the second period. More noninvasive ventilation and less conventional mechanical ventilation were used, and less inotropic support was needed, with no significant differences. The antibiotherapy rate decreased significantly (P=.003). CONCLUSIONS Despite the decrease in antibiotherapy, the use of nebulizations and glucocorticoids in these patients should be limited, as recommended by the guide.
Collapse
Affiliation(s)
- C Guitart
- Unidad de Cuidados Intensivos Pediátricos (UCIP), Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, España
| | - C Alejandre
- Unidad de Cuidados Intensivos Pediátricos (UCIP), Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, España.
| | - I Torrús
- Servicio de Pediatría, Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, España
| | - M Balaguer
- Unidad de Cuidados Intensivos Pediátricos (UCIP), Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, España
| | - E Esteban
- Unidad de Cuidados Intensivos Pediátricos (UCIP), Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, España
| | - F J Cambra
- Unidad de Cuidados Intensivos Pediátricos (UCIP), Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, España
| | - I Jordan
- Unidad de Cuidados Intensivos Pediátricos (UCIP), Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, España
| |
Collapse
|
7
|
Gadgeel S, Rodriguez-Abreu D, Felip E, Esteban E, Speranza G, Reck M, Hui R, Boyer M, Garon E, Horinouchi H, Cristescu R, Aurora-Garg D, Lunceford J, Kobie J, Ayers M, Piperdi B, Pietanza M, Garassino M. KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz453.002] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Gadgeel S, Garassino M, Esteban E, Speranza G, Felip E, Hochmair M, Powell S, Cheng SS, Bischoff H, Peled N, Hui R, Reck M, Kurata T, Garon E, Boyer M, Yang J, Pietanza M, Rodríguez-Abreu D. O.03 KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab + Chemotherapy for Metastatic Nonsquamous NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.09.090] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
9
|
Suarez Rodriguez C, Arranz Arija J, Morales Barrera R, Puente J, Reig O, Faez L, González del Alba A, Valderrama B, Gallardo E, Mellado B, Esteban E, Jimenez J, Vivancos A, Carles J. mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz249.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Massuti Sureda B, Sanchez Torres J, Cobo Dols M, Moran Bueno M, Gonzalez-Larriba J, Barneto Aranda I, De Castro Carpeno J, Iglesias L, Muñoz M, López Vivanco G, Isla Casado M, López R, de las Penas Bataller R, Rodriguez Abreu D, Artal-Cortes A, Esteban E, Provencio M, Pereira E, Sanchez-Paya J, Rosell R. BRCA1 expression level as prognostic factor for recurrence in resected NSCLC with adjuvant chemotherapy: SCAT Trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Garassino M, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, Speranza G, Reck M, Hui R, Boyer M, Cristescu R, Aurora-Garg D, Albright A, Loboda A, Kobie J, Lunceford J, Ayers M, Lubiniecki G, Piperdi B, Pietanza M, Garon E. OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.427] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
12
|
Massuti B, Sanchez J, Cobo M, Moran T, Larriba JG, Barneto I, De Castro Carpeno J, Iglesias L, Muñoz M, López-Vivanco G, Isla D, López R, De Las Penas R, Rodriguez-Abreu D, Artal A, Esteban E, Provencio M, Pereira E, Sanchez-Payá J, Rosell R. MA02.01 Reccurrence Pattern After Adjuvant Customized Chemotherapy Based on BRCA Expression Level (SCAT Trial). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Grimm MO, Schmidinger M, Duran Martinez I, Schinzari G, Esteban E, Schmitz M, Schumacher U, Baretton G, Barthelemy P, Melichar B, Charnley N, Schrijvers D, Albiges L. Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.051] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Yébenes JC, Lorencio C, Esteban E, Espinosa L, Badia JM, Capdevila JA, Cisteró B, Moreno S, Calbo E, Jiménez-Fábrega X, Clèries M, Faixedas MT, Ferrer R, Vela E, Medina C, Rodríguez A, Netto C, Armero E, Solsona M, Lopez R, Granes A, Perez-Claveria V, Artigas A, Estany J. Interhospital Sepsis Code in Catalonia (Spain): Territorial model for initial care of patients with sepsis. Med Intensiva 2019; 44:36-45. [PMID: 31542182 DOI: 10.1016/j.medin.2019.05.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2019] [Revised: 05/10/2019] [Accepted: 05/27/2019] [Indexed: 12/29/2022]
Abstract
Sepsis is a syndromic entity with high prevalence and mortality. The management of sepsis is standardized and exhibits time-dependent efficiency. However, the management of patients with sepsis is complex. The heterogeneity of the forms of presentation can make it difficult to detect and manage such cases, in the same way as differences in training, professional competences or the availability of health resources. The Advisory Commission for Patient Care with Sepsis (CAAPAS), comprising 7 scientific societies, the Emergency Medical System (SEM) and the Catalan Health Service (CatSalut), have developed the Interhospital Sepsis Code (CSI) in Catalonia (Spain). The general objective of the CSI is to increase awareness, promote early detection and facilitate initial care and interhospital coordination to attend septic patients in a homogeneous manner throughout Catalonia.
Collapse
Affiliation(s)
- J C Yébenes
- Servei de Medicina Intensiva, Hospital de Mataró, Mataró, España.
| | - C Lorencio
- Servei de Medicina Intensiva, Hospital Universitari Dr. Josep Trueta, Girona, España
| | - E Esteban
- Servei de Medicina Intensiva, Hospital Sant Joan de Déu, Barcelona, España
| | - L Espinosa
- Consorci Sanitari de Barcelona, CatSalut-Servei Català de la Salut, Barcelona, España
| | - J M Badia
- Servei de Cirurgia General, Hospital Fundació Asil de Granollers, Granollers, España
| | - J A Capdevila
- Servei de Medicina Interna, Hospital de Mataró, Mataró, España
| | - B Cisteró
- Servei d'Urgències, Corporació Sanitària Parc Taulí, Sabadell, España
| | - S Moreno
- Àrea Bàsica de Salut Gràcia, Barcelona, España
| | - E Calbo
- Servei de Medicina Interna-Malalties Infeccioses, Hospital Mutua de Terrassa, Terrassa, España
| | | | - M Clèries
- Unitat d'Informació i Coneixement, CatSalut-Servei Català de la Salut, Barcelona, España
| | - M T Faixedas
- Oficina Tècnica dels Registres de Codis d'Activació, CatSalut-Servei Català de la Salut, Barcelona, España
| | - R Ferrer
- Servei de Medicina Intensiva, Hospital Universitari Vall d'Hebron, Barcelona, España
| | - E Vela
- Unitat d'Informació i Coneixement, CatSalut-Servei Català de la Salut, Barcelona, España
| | - C Medina
- Oficina Tècnica dels Registres de Codis d'Activació, CatSalut-Servei Català de la Salut, Barcelona, España
| | - A Rodríguez
- Servei de Medicina Intensiva, Hospital Universitari Joan XXIII, Tarragona, España
| | - C Netto
- Servei d'Urgències, Corporació Sanitària Parc Taulí, Sabadell, España
| | - E Armero
- Servei d'Urgències, Hospital Comarcal de Blanes, Blanes, España
| | - M Solsona
- Servei de Medicina Intensiva, Hospital de Mataró, Mataró, España
| | - R Lopez
- Consorci Sanitari de Barcelona, CatSalut-Servei Català de la Salut, Barcelona, España
| | - A Granes
- Sistema d'Emergències Mèdiques (SEM)
| | | | - A Artigas
- Servei de Medicina Intensiva, Corporació Sanitària Parc Taulí, Sabadell, España
| | - J Estany
- Consorci Sanitari de Barcelona, CatSalut-Servei Català de la Salut, Barcelona, España
| | | |
Collapse
|
15
|
Rodriguez Abreu D, Garassino M, Esteban E, Speranza G, Felip E, Domine M, Hochmair M, Powell S, Cheng SS, Bischoff H, Peled N, Hui R, Reck M, Garon E, Boyer M, Grossi F, Jennens R, Yang J, Pietanza M, Gadgeel S. KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes? Ann Oncol 2018. [DOI: 10.1093/annonc/mdy425.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Rodriguez Abreu D, Garassino M, Esteban E, Speranza G, Felip E, Domine M, Hochmair M, Powell S, Cheng SS, Bischoff H, Peled N, Hui R, Reck M, Garon E, Boyer M, Grossi F, Jennens R, Yang J, Pietanza M, Gadgeel S. KEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes? Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.086] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Puente J, Mendez Vidal M, Saez M, Font Pous A, Duran I, Castellano D, Juan Fita M, Santander C, Arranz Arija J, Sanchez-Hernandez A, Mellado B, Alonso T, Gonzalez del Alba Baamonde M, Maroto P, Lazaro M, Esteban E, Cassinello J, Climent Duran M. Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy284.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
18
|
Garassino M, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, Speranza G, Domine M, Hochmair M, Powell S, Cheng S, Bischoff H, Peled N, Reck M, Hui R, Garon E, Boyer M, Yang J, Burke T, Pietanza M, Gandhi L. PD.1.01 Health-Related Quality of Life with Pembrolizumab or Placebo + Pemetrexed + Platinum in Non-Squamous NSCLC: KEYNOTE-189. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.07.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Kus S, Coenen M, Simmel S, Esteban E, Kirschneck M, Seyfried F, Bühren V. ICF-basierte Prädiktion des Outcomes in der Rehabilitation nach Trauma (icfPROreha) – Identifizierung potenzieller Prädiktoren sowie von Messverfahren zur Prognose der Arbeitsfähigkeit und Lebensqualität nach schweren muskuloskeletalen Verletzungen. Das Gesundheitswesen 2018. [DOI: 10.1055/s-0038-1667735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- S Kus
- ICF Research Branch, ein Kooperationspartner des WHO Collaborating Centre for the Family of International Classifications in Deutschland (am DIMDI), Nottwil, Schweiz
| | - M Coenen
- Ludwig-Maximilians-Universität München, Lehrstuhl für Public Health und Versorgungsforschung, Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie – IBE, München, Deutschland
- ICF Research Branch, ein Kooperationspartner des WHO Collaborating Centre for the Family of International Classifications in Deutschland (am DIMDI), Nottwil, Schweiz
| | - S Simmel
- Berufsgenossenschaftliche Unfallklinik Murnau, Abteilung BG Rehabilitation, Murnau, Deutschland
| | - E Esteban
- Ludwig-Maximilians-Universität München, Lehrstuhl für Public Health und Versorgungsforschung, Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie – IBE, München, Deutschland
| | - M Kirschneck
- Ludwig-Maximilians-Universität München, Lehrstuhl für Public Health und Versorgungsforschung, Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie – IBE, München, Deutschland
- ICF Research Branch, ein Kooperationspartner des WHO Collaborating Centre for the Family of International Classifications in Deutschland (am DIMDI), Nottwil, Schweiz
| | - F Seyfried
- Ludwig-Maximilians-Universität München, Lehrstuhl für Public Health und Versorgungsforschung, Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie – IBE, München, Deutschland
| | - V Bühren
- Berufsgenossenschaftliche Unfallklinik Murnau, Abteilung BG Rehabilitation, Murnau, Deutschland
| |
Collapse
|
20
|
Esteban E, Buckley CJ, Wilkens PJ. P2‐439: IDENTIFICATION OF FTD CANDIDATES IN MCI‐SNAP GROUPS BY CORTICAL THICKNESS ANALYSIS. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.1131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
21
|
Esteban E, Coenen M, Ito E, Gruber S, Scaratti C, Leonardi M, Roka O, Vasilou E, Muñoz-Murillo A, Ávila CC, Kovačič DS, Ivandic I, Sabariego C. Views and Experiences of Persons with Chronic Diseases about Strategies that Aim to Integrate and Re-Integrate Them into Work: A Systematic Review of Qualitative Studies. Int J Environ Res Public Health 2018; 15:E1022. [PMID: 29783671 PMCID: PMC5982061 DOI: 10.3390/ijerph15051022] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/14/2018] [Revised: 05/15/2018] [Accepted: 05/16/2018] [Indexed: 12/18/2022]
Abstract
The effectiveness of strategies targeting professional integration and reintegration strongly depends on the experiences of participants. The aim of this systematic literature review is to synthesize European qualitative studies exploring views and experiences of persons with chronic conditions regarding strategies for integration and reintegration into work. The systematic search was conducted in Medline, PsycINFO, CDR-HTA, CDR-DARE and Cochrane Systematic Reviews. Overall, 24 studies published in English between January 2011 and April 2016 were included. Most studies were carried out in Nordic countries or in the UK, and most participants were persons with either mental or musculoskeletal disorders. Ten themes emerged: individual and holistic approach, clarity of strategy and processes, timing of rehabilitation processes, experience with professionals, at the workplace and with peer groups, changes in the understanding of health and work, active involvement in the process, competencies development and motivating aspects of work. Findings highlight, among others, the need to actively involve participants in the return to work process and to provide timely and clearly structured processes and interventions. This review provides stakeholders key information to develop, plan, implement and evaluate interventions to integrate and re-integrate persons with chronic conditions into work in Europe.
Collapse
Affiliation(s)
- Eva Esteban
- Department of Medical Information Processing, Biometry and Epidemiology (IBE), Chair for Public Health and Health Services Research, Research Unit for Biopsychosocial Health, Ludwig-Maximilians-Universität (LMU), 81377 Munich, Germany.
| | - Michaela Coenen
- Department of Medical Information Processing, Biometry and Epidemiology (IBE), Chair for Public Health and Health Services Research, Research Unit for Biopsychosocial Health, Ludwig-Maximilians-Universität (LMU), 81377 Munich, Germany.
| | - Elizabeth Ito
- Department of Medical Information Processing, Biometry and Epidemiology (IBE), Chair for Public Health and Health Services Research, Research Unit for Biopsychosocial Health, Ludwig-Maximilians-Universität (LMU), 81377 Munich, Germany.
| | - Sonja Gruber
- Disability and Diversity Studies, Carinthia University of Applied Science (CUAS), 9020 Klagenfurt, Austria.
| | - Chiara Scaratti
- Neurology, Public Health and Disability Unit, Neurological Institute Carlo Besta IRCCS Foundation, 20133 Milan, Italy.
| | - Matilde Leonardi
- Neurology, Public Health and Disability Unit, Neurological Institute Carlo Besta IRCCS Foundation, 20133 Milan, Italy.
| | - Olga Roka
- Department of Special Education, University of Thessaly, 38221 Volos, Greece.
| | - Evdokia Vasilou
- Department of Special Education, University of Thessaly, 38221 Volos, Greece.
| | - Amalia Muñoz-Murillo
- Research Unit, Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Sant Boi de Llobregat, 08830 Barcelona, Spain.
| | - Carolina C Ávila
- Department of Psychiatry, Universidad Autónoma de Madrid and Institute of Health Carlos III, CIBER of Mental Health (CIBERSAM), 28038 Madrid, Spain.
| | - Dare S Kovačič
- Development Center for Vocational Rehabilitation, University Rehabilitation Institute, Republic of Slovenia, 1000 Ljubljana, Slovenia.
| | - Ivana Ivandic
- Department of Medical Information Processing, Biometry and Epidemiology (IBE), Chair for Public Health and Health Services Research, Research Unit for Biopsychosocial Health, Ludwig-Maximilians-Universität (LMU), 81377 Munich, Germany.
| | - Carla Sabariego
- Department of Medical Information Processing, Biometry and Epidemiology (IBE), Chair for Public Health and Health Services Research, Research Unit for Biopsychosocial Health, Ludwig-Maximilians-Universität (LMU), 81377 Munich, Germany.
| |
Collapse
|
22
|
Muñoz-Murillo A, Esteban E, Ávila CC, Fheodoroff K, Haro JM, Leonardi M, Olaya B. Furthering the Evidence of the Effectiveness of Employment Strategies for People with Mental Disorders in Europe: A Systematic Review. Int J Environ Res Public Health 2018; 15:E838. [PMID: 29695093 PMCID: PMC5981877 DOI: 10.3390/ijerph15050838] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Revised: 04/18/2018] [Accepted: 04/20/2018] [Indexed: 12/11/2022]
Abstract
(1) Purpose: This systematic review aims to assess the effectiveness of strategies used in the professional (re)integration of persons with mental disorders (MD) in European countries; (2) Methods: We conducted a search for scientific publications available in relevant electronic databases (Medline, PsycINFO, CDR-HTA, CDR-DARE, and Cochrane Library). The present study collected evidence on the effectiveness, from 2011 to 2016, of employment strategies for persons with MDs; (3) Results: A total of 18 studies were included, representing 5216 participants (aged 18⁻65, mean age of 38.5 years old) from 7 countries. Job access programs demonstrated effectiveness in four out of six studies. Return to work (RTW) interventions showed significant positive results in two studies, while four studies did not refer to effectiveness. There were inconsistent results in another four studies; (4) Conclusions: Our findings highlight the complexities of the implementation of employment strategies (job access and return to work). Job access strategies seem to improve employment outcomes. The effectiveness of return to work strategies remains unclear. The involvement and commitment of physicians, employment specialists, and employers, and employees capacity for self-care seem decisive for employment re-integration success. Further analyses are needed to assess the cost-effectiveness of these interventions and corroborate our results, with longer follow-ups.
Collapse
Affiliation(s)
- Amalia Muñoz-Murillo
- Research, Innovation and Teaching Unit, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, 08830 Barcelona, Spain.
- Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Fundació Sant Joan de Déu, Sant Boi de Llobregat, 08830 Barcelona, Spain.
| | - Eva Esteban
- Department of Medical Information Processing, Biometry and Epidemiology (IBE), Chair for Public Health and Health Services Research, Research Unit for Biopsychosocial Health, Ludwig-Maximilians-Universität (LMU), 81377 Munich, Germany.
| | - Carolina C Ávila
- Department of Psychiatry, Universidad Autónoma de Madrid and CIBER of Mental Health (CIBERSAM), 28049 Madrid, Spain.
| | | | - Josep Maria Haro
- Research, Innovation and Teaching Unit, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, 08830 Barcelona, Spain.
- Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Fundació Sant Joan de Déu, Sant Boi de Llobregat, 08830 Barcelona, Spain.
- Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), 28029 Madrid, Spain.
| | - Matilde Leonardi
- Neurology, Public Health and Disability Unit, Neurological Institute C. Besta IRCCS Foundation, 20133 Milan, Italy.
| | - Beatriz Olaya
- Research, Innovation and Teaching Unit, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, 08830 Barcelona, Spain.
- Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, Fundació Sant Joan de Déu, Sant Boi de Llobregat, 08830 Barcelona, Spain.
- Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), 28029 Madrid, Spain.
| |
Collapse
|
23
|
Foitzek N, Ávila CC, Ivandic I, Bitenc Č, Cabello M, Gruber S, Leonardi M, Muñoz-Murillo A, Scaratti C, Tobiasz-Adamczyk B, Vlachou A, Esteban E, Sabariego C, Coenen M. What Persons with Chronic Health Conditions Need to Maintain or Return to Work-Results of an Online-Survey in Seven European Countries. Int J Environ Res Public Health 2018; 15:ijerph15040595. [PMID: 29587433 PMCID: PMC5923637 DOI: 10.3390/ijerph15040595] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Revised: 03/19/2018] [Accepted: 03/22/2018] [Indexed: 11/16/2022]
Abstract
Chronic health conditions represent the major share of the disease burden in Europe and have a significant impact on work. This study aims to: (1) identify factors that have a negative or positive impact on the work lives of persons with chronic health conditions; (2) explore the needs of these persons to maintain a job or return to work and (3) compare these results with respect to these persons' occupational status. An online survey was performed in seven European countries. Open-ended survey questions were analyzed using qualitative methods. In total, 487 participants with six chronic health conditions participated. The majority of participants named work-related aspects (such as career development, stress at the workplace, work structure and schedule as well as workload), support of others and attitudes of others as being the factors positively and negatively impact their work lives the most. Our study shed light on the importance of changing the attitudes of supervisors and co-workers to counteract stigmatization of persons with chronic health conditions in the workplace. In conclusion, this study provides a basis for developing new strategies of integration and reintegration at work for persons with chronic health conditions in European countries.
Collapse
Affiliation(s)
- Nicole Foitzek
- Chair for Public Health and Health Services Research, Research Unit for Biopsychosocial Health, Department of Medical Information Processing, Biometry and Epidemiology (IBE), Ludwig-Maximilians-Universität (LMU), 81377 Munich, Germany.
| | - Carolina C Ávila
- Department of Psychiatry, Universidad Autónoma de Madrid and Institute of Health Carlos III, CIBER of Mental Health (CIBERSAM), 28038 Madrid, Spain.
| | - Ivana Ivandic
- Chair for Public Health and Health Services Research, Research Unit for Biopsychosocial Health, Department of Medical Information Processing, Biometry and Epidemiology (IBE), Ludwig-Maximilians-Universität (LMU), 81377 Munich, Germany.
| | - Črtomir Bitenc
- Development Center for Vocational Rehabilitation, University Rehabilitation Institute Republic of Slovenia, 1000 Ljubljana, Slovenia.
| | - Maria Cabello
- Department of Psychiatry, Universidad Autónoma de Madrid and Institute of Health Carlos III, CIBER of Mental Health (CIBERSAM), 28038 Madrid, Spain.
| | - Sonja Gruber
- Disability and Diversity Studies, Carinthia University of Applied Science (CUAS), 9020 Klagenfurt, Austria.
| | - Matilde Leonardi
- Neurology, Public Health and Disability Unit; Neurological Institute Carlo Besta IRCCS Foundation, 20133 Milan, Italy.
| | - Amalia Muñoz-Murillo
- Research Unit, Parc Sanitari Sant Joan de Déu, Universitat de Barcelona, 08830 Sant Boi de Llobregat, Barcelona, Spain.
| | - Chiara Scaratti
- Neurology, Public Health and Disability Unit; Neurological Institute Carlo Besta IRCCS Foundation, 20133 Milan, Italy.
| | - Beata Tobiasz-Adamczyk
- Chair of Epidemiology and Preventive Medicine, Jagiellonian University Medical College, 31-034 Krakow, Poland.
| | - Anastasia Vlachou
- Department of Special Education, University of Thessaly, 38221 Volos, Greece.
| | - Eva Esteban
- Chair for Public Health and Health Services Research, Research Unit for Biopsychosocial Health, Department of Medical Information Processing, Biometry and Epidemiology (IBE), Ludwig-Maximilians-Universität (LMU), 81377 Munich, Germany.
| | - Carla Sabariego
- Chair for Public Health and Health Services Research, Research Unit for Biopsychosocial Health, Department of Medical Information Processing, Biometry and Epidemiology (IBE), Ludwig-Maximilians-Universität (LMU), 81377 Munich, Germany.
| | - Michaela Coenen
- Chair for Public Health and Health Services Research, Research Unit for Biopsychosocial Health, Department of Medical Information Processing, Biometry and Epidemiology (IBE), Ludwig-Maximilians-Universität (LMU), 81377 Munich, Germany.
| |
Collapse
|
24
|
Sabariego C, Coenen M, Ito E, Fheodoroff K, Scaratti C, Leonardi M, Vlachou A, Stavroussi P, Brecelj V, Kovačič DS, Esteban E. Effectiveness of Integration and Re-Integration into Work Strategies for Persons with Chronic Conditions: A Systematic Review of European Strategies. Int J Environ Res Public Health 2018; 15:ijerph15030552. [PMID: 29562715 PMCID: PMC5877097 DOI: 10.3390/ijerph15030552] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Revised: 03/13/2018] [Accepted: 03/16/2018] [Indexed: 12/16/2022]
Abstract
Due to low employment rates associated to chronic conditions in Europe, it is essential to foster effective integration and re-integration into work strategies. The objective of this systematic review is to summarize the evidence on the effectiveness of strategies for integration and re-integration to work for persons with chronic diseases or with musculoskeletal disorders, implemented in Europe in the past five years. A systematic search was conducted in MedLine, PsycINFO, CDR-HTA, CDR-DARE and Cochrane Systematic Reviews. Overall, 32 relevant publications were identified. Of these, 21 were considered eligible after a methodological assessment and included. Positive changes in employment status, return to work and sick leave outcomes were achieved with graded sickness-absence certificates, part-time sick leave, early ergonomic interventions for back pain, disability evaluation followed by information and advice, and with multidisciplinary, coordinated and tailored return to work interventions. Additionally, a positive association between the co-existence of active labour market policies to promote employment and passive support measures (e.g., pensions or benefits) and the probability of finding a job was observed. Research on the evaluation of the effectiveness of strategies targeting integration and re-integration into work for persons with chronic health conditions needs, however, to be improved and strengthened.
Collapse
Affiliation(s)
- Carla Sabariego
- Research Unit for Biopsychosocial Health, Department of Medical Information Processing, Biometry and Epidemiology (IBE), Ludwig-Maximilians-Universität (LMU), 81377 Munich, Germany.
| | - Michaela Coenen
- Research Unit for Biopsychosocial Health, Department of Medical Information Processing, Biometry and Epidemiology (IBE), Ludwig-Maximilians-Universität (LMU), 81377 Munich, Germany.
| | - Elizabeth Ito
- Research Unit for Biopsychosocial Health, Department of Medical Information Processing, Biometry and Epidemiology (IBE), Ludwig-Maximilians-Universität (LMU), 81377 Munich, Germany.
| | | | - Chiara Scaratti
- Neurology, Public Health and Disability Unit; Neurological Institute C. Besta IRCCS Foundation, 20133 Milan, Italy.
| | - Matilde Leonardi
- Neurology, Public Health and Disability Unit; Neurological Institute C. Besta IRCCS Foundation, 20133 Milan, Italy.
| | - Anastasia Vlachou
- Department of Special Education, University of Thessaly, 38221 Volos, Greece.
| | | | - Valentina Brecelj
- Development Centre for Vocational Rehabilitation, University Rehabilitation Institute Republic of Slovenia, 1000 Ljubljana, Slovenia.
| | - Dare S Kovačič
- Development Centre for Vocational Rehabilitation, University Rehabilitation Institute Republic of Slovenia, 1000 Ljubljana, Slovenia.
| | - Eva Esteban
- Research Unit for Biopsychosocial Health, Department of Medical Information Processing, Biometry and Epidemiology (IBE), Ludwig-Maximilians-Universität (LMU), 81377 Munich, Germany.
| |
Collapse
|
25
|
Maroto P, Esteban E, Parra EF, Mendez-Vidal MJ, Domenech M, Pérez-Valderrama B, Calderero V, Pérez-Gracia JL, Grande E, Algaba F. HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma. Onco Targets Ther 2017; 10:4635-4643. [PMID: 29033582 PMCID: PMC5614781 DOI: 10.2147/ott.s137677] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Clear-cell renal cell carcinoma (ccRCC) is a heterogeneous disease with a different clinical behavior and response to targeted therapies. Differences in hypoxia-inducible factor (HIF) expression have been used to classify von Hippel-Lindau gene (VHL)-deficient ccRCC tumors. c-Myc may be driving proliferation in HIF-2α-expressing tumors in a growth factor-independent manner. OBJECTIVE To explore the HIF-1α, HIF-2α and c-Myc baseline expression as potential predictors of sunitinib outcome as well as the effectiveness and safety with sunitinib in patients with metastatic ccRCC in routine clinical practice. METHODS This was an observational and prospective study involving 10 Spanish hospitals. Formalin-fixed, paraffin-embedded primary tumor samples from metastatic ccRCC patients who received sunitinib as first-line treatment were analyzed. Association between biomarker expression and sunitinib treatment outcomes was evaluated. Kaplan-Meier method was applied to measure progression-free survival (PFS) and overall survival. RESULTS Eighty-one patients were included: median PFS was 10.8 months (95% CI: 7.4-13.5 months), median overall survival was 21.8 months (95% CI: 14.7-29.8 months) and objective response rate was 40.7%, with 7.4% of patients achieving a complete response. Molecular marker staining was performed in the 69 available tumor samples. Significant association with lower PFS was identified for double c-Myc/HIF-2α-positive staining tumors (median 4.3 vs 11.5 months, hazard ratio =2.64, 95% CI: 1.03-6.80, P=0.036). A trend toward a lower PFS was found in positive c-Myc tumors (median 5.9 vs 10.9 months, P=0.263). HIF-1α and HIF-2α expression levels were not associated with clinical outcome. CONCLUSION These preliminary results suggest that predictive subgroups might be defined based on biomarkers such as c-Myc/HIF-2α. Further validation with more patients will be needed in order to confirm it. Outcomes with sunitinib in metastatic ccRCC in daily clinical practice resemble those obtained in clinical trials.
Collapse
Affiliation(s)
- P Maroto
- Department of Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona
| | - E Esteban
- Department of Oncology, Nuevo HUCA, Oviedo
| | | | | | - M Domenech
- Department of Oncology, Hospital de Althaia Xarxa Asistencial Manresa, Barcelona
| | | | - V Calderero
- Department of Oncology, H. Fundación Miguel Servet, Zaragoza
| | - J L Pérez-Gracia
- Department of Oncology, Clinica Universitaria de Pamplona, Pamplona
| | - E Grande
- Department of Oncology, H. Ramón y Cajal, Madrid
| | - F Algaba
- Pathology Unit, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|
26
|
Revuelta A, Rodríguez Rubí D, Sánchez Lorenzo M, Ruiz Echeverria L, Li W, Solís Hernández M, Fáez García L, Fernández Arrojo S, Iglesias Gómez C, Villanueva Palicio N, Jimenez Fonseca P, Luque Cabal M, Álvarez Fernández C, Izquierdo M, Viéitez J, Esteban E. Experience with the implant of vascular access devices by medical oncologist in a non-surgical scenery. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx388.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Garcia-Donas J, Lainez N, Santos-Romero M, Puente J, Castellano D, Rodriguez-Moreno J, Esteban E, Grande Pulido E, Fernandez Parra E, Rodriguez Lajusticia L, Domenech M, Gonzalez Billalabeitia E, Sáez M, Gallardo Diaz E, Hernando Polo S, Herrador A, Inglada-Pérez L, Robledo M, Rodriguez-Antona C. Prospective study assessing the expression of angiogenesis-related genes as markers of anti-VEGFR2 response in advanced renal cell carcinoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Sanmamed MF, Esteban E, Uriol E, Zarate R, Capelan M, Muriel C, Crespo G, Berros JP, Pardo-Coto P, Perez Q, Alvarez-Fernández C, Jiménez Fonseca P, Luque M, Astudillo A. Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours. J Transl Med 2017; 15:62. [PMID: 28320414 PMCID: PMC5358043 DOI: 10.1186/s12967-017-1162-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Accepted: 03/10/2017] [Indexed: 11/10/2022] Open
Abstract
Background Inguinal orchiectomy is curative in 70–80% of clinical stage I testicular germ cell tumours (CS I TGCT). The identification of patients who are at low risk of relapse is critical to avoid unnecessary treatment. The aim of this study is to explore EGFR, hMLH-1/hMSH-2 and microsatellite instability (MSI) as potential prognostic factors of recurrence in CS I TGCT. Methods Fifty-six CS I TGCT patients who underwent inguinal orchiectomy were included in this study. We analysed the relationship between clinicopathological and molecular factors with survival. Analysis of hMLH1, hMSH2 and EGFR expression was carried out by immunohistochemistry. Methylation status of the hMLH1 promoter was determined by pyrosequencing analysis in selected cases. EGFR exons 19, 20, 21 were analysed by PCR labeled-fragments and MSI status was determined using standard Multiplex MSI assays. Results Classical pathological factors such as lymphovascular invasion, high percentage of embryonal carcinoma, rete testis invasion or tumour size ≥4 cm showed a significant relationship with a higher risk of relapse. Additionally, it was found that an epididymis invasion proved to be a significant independent poor prognostic factor of recurrence (p = 0.001). hMLH1 or hMSH2 expression showed no significant association with risk of relapse and no MSI was found. EGFR expression was observed in 30.4% of samples and its expression was associated with higher risk of relapse (HR 3.5; 95% CI 1.3–9.8; p = 0.016). None of the cases presented EGFR kinase domain mutations. Conclusions Epididymis invasion and EGFR expression, but not hMLH-1/hMSH-2 or MSI, could be potentially useful as new prognostic factors of recurrence for CS I TGCT. Electronic supplementary material The online version of this article (doi:10.1186/s12967-017-1162-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Miguel F Sanmamed
- Department of Immunobiology, School of Medicine, Yale University, 300 George Street, Suite 203A, New Haven, CT, 06511, USA. .,Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain.
| | - E Esteban
- Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - E Uriol
- Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - R Zarate
- Clinical Genetics Unit, Clínica Universidad de Navarra, Pamplona, Spain
| | - M Capelan
- Breast Unit, Royal Marsden NHS Foundation Trust, London, UK
| | - C Muriel
- Department of Medical Oncology, Hospital Regional Universitario Carlos Haya, Málaga, Spain
| | - G Crespo
- Department of Medical Oncology, Hospital Universitario de Burgos, Burgos, Spain
| | - J P Berros
- Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - P Pardo-Coto
- Department of Medical Oncology, Centro Médico de Asturias, Oviedo, Spain
| | - Q Perez
- Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - C Alvarez-Fernández
- Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - P Jiménez Fonseca
- Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - M Luque
- Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - A Astudillo
- Department of Pathology, Hospital Universitario Central de Asturias, Oviedo, Spain
| |
Collapse
|
29
|
Gómez J, Yunta F, Esteban E, Carpena RO, Zornoza P. Use of radiometric indices to evaluate Zn and Pb stress in two grass species (Festuca rubra L. and Vulpia myuros L.). Environ Sci Pollut Res Int 2016; 23:23239-23248. [PMID: 27638786 DOI: 10.1007/s11356-016-7546-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Accepted: 08/29/2016] [Indexed: 05/04/2023]
Abstract
Vegetation indices obtained from radiometric measurements have been used to estimate the stress response of plants grown in contaminated sites. The phytotoxicity of Pb and Zn in Festuca rubra L. and Vulpia myuros L. plants grown under hydroponic conditions was evaluated using vegetation indices obtained from radiometric measurements. The plants were supplied with 3 mM Zn (+Zn), 500 μM Pb (+Pb) and 500 μM Pb with EDTA (+PbEDTA) for 3 months. Significantly higher Zn concentrations in F. rubra shoots compared with V. myuros shoots were detected for Zn and Pb treatments. EDTA increased Pb transport to the shoots for both grasses, while Pb-treated plants retained Pb primarily in the roots. All vegetation indices tested showed the highest differences in F. rubra under +PbEDTA treatment and minor effects under +Zn, whereas the major variations for V. myuros corresponded to +Zn treatment, followed by +PbEDTA. Red edge normalized difference vegetation index, yellowness index and anthocyanin concentration index were the most sensitive indices to report Zn and Pb phytotoxicity in these grasses. According to the results obtained, both metal concentrations and radiometric indices suggested that Pb is more phytotoxic to F. rubra, which tolerates high Zn levels, whereas V. myuros was strongly affected by high Zn levels and markedly tolerant to Pb, even when applied in a mobile form (PbEDTA). Both species could be used in the phytostabilization of Zn- and Pb-contaminated soils. The abilities of F. rubra to accumulate Zn and V. myuros to accumulate Pb in the roots would facilitate a more efficient phytoremediation strategy when used in combination.
Collapse
Affiliation(s)
- J Gómez
- Dpto. Química Agrícola y Bromatología. Facultad de Ciencias, Universidad Autónoma de Madrid, C/Francisco Tomás y Valiente 7, 28049, Madrid, Spain
| | - F Yunta
- Dpto. Química Agrícola y Bromatología. Facultad de Ciencias, Universidad Autónoma de Madrid, C/Francisco Tomás y Valiente 7, 28049, Madrid, Spain
| | - E Esteban
- Dpto. Química Agrícola y Bromatología. Facultad de Ciencias, Universidad Autónoma de Madrid, C/Francisco Tomás y Valiente 7, 28049, Madrid, Spain.
| | - R O Carpena
- Dpto. Química Agrícola y Bromatología. Facultad de Ciencias, Universidad Autónoma de Madrid, C/Francisco Tomás y Valiente 7, 28049, Madrid, Spain
| | - P Zornoza
- Dpto. Química Agrícola y Bromatología. Facultad de Ciencias, Universidad Autónoma de Madrid, C/Francisco Tomás y Valiente 7, 28049, Madrid, Spain
| |
Collapse
|
30
|
Esteban E, Palacio J, Estella R. Deformidad de pie en paciente diabético. Fractura-luxación de Lisfranc: a propósito de un caso. Semergen 2016; 42:336-8. [DOI: 10.1016/j.semerg.2015.05.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2015] [Revised: 05/18/2015] [Accepted: 05/19/2015] [Indexed: 10/23/2022]
|
31
|
Calvo Temprano D, Esteban E, Jiménez Fonseca P, Fernández-Mariño B. CT scan prior to radiotherapy in unresectable, locally advanced, non-small cell carcinoma of the lung: is it always necessary? Clin Transl Oncol 2016; 19:105-110. [PMID: 27091132 DOI: 10.1007/s12094-016-1510-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Accepted: 04/05/2016] [Indexed: 11/26/2022]
Abstract
PURPOSE There is broad consensus regarding evaluating response to chemotherapy (CHT) by means of computerized tomography (CT) in patients with localized or locally advanced non-small cell lung carcinoma (NSCLC). We present a study comparing the usefulness of CT versus chest X-ray (XR) and clinical findings when indicating radiotherapy (RT) following CHT. METHODS Ninety-eight of 150 subjects with unresectable locally advanced NSCLC were blindly and independently evaluated by XR and CT, with pairs of chest XR and CT (before and after CHT). A null hypothesis (H0) was established of the conditioned probability of detecting progression by CT and not by XR of 10 % or more, with a statistical power of 80 %. RESULTS Sensitivity, specificity, positive and negative predictive value of XR versus CT were 98, 89, 99, and 80 % respectively. A 4 % (p = 0.0451) probability of improvement of CT versus XR was calculated, enabling the H0 to be ruled out. CONCLUSION The CT failed to prove to be significantly superior to the chest XR + clinical picture in indicating a change in treatment approach in patients with unresectable locally advanced NSCLC after CHT.
Collapse
MESH Headings
- Adenocarcinoma/diagnostic imaging
- Adenocarcinoma/pathology
- Adenocarcinoma/radiotherapy
- Adult
- Aged
- Carcinoma, Large Cell/diagnostic imaging
- Carcinoma, Large Cell/pathology
- Carcinoma, Large Cell/radiotherapy
- Carcinoma, Non-Small-Cell Lung/diagnostic imaging
- Carcinoma, Non-Small-Cell Lung/pathology
- Carcinoma, Non-Small-Cell Lung/radiotherapy
- Carcinoma, Squamous Cell/diagnostic imaging
- Carcinoma, Squamous Cell/pathology
- Carcinoma, Squamous Cell/radiotherapy
- Female
- Follow-Up Studies
- Humans
- Lung Neoplasms/diagnostic imaging
- Lung Neoplasms/pathology
- Lung Neoplasms/radiotherapy
- Male
- Middle Aged
- Neoplasm Staging
- Prognosis
- Radiography, Thoracic/methods
- Tomography, X-Ray Computed/methods
Collapse
Affiliation(s)
- D Calvo Temprano
- Radiology Service, Hospital Universitario Central de Asturias, Avenida de Roma, s/n, ES-33011, Oviedo, Asturias, Spain.
| | - E Esteban
- Medical Oncology Service, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
| | - P Jiménez Fonseca
- Medical Oncology Service, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
| | - B Fernández-Mariño
- Radiology Service, Hospital Universitario Central de Asturias, Avenida de Roma, s/n, ES-33011, Oviedo, Asturias, Spain
| |
Collapse
|
32
|
Caipo M, Cahill S, Kenny M, Wachsmuth K, Toyofuku H, Hielm S, Carolissen V, Bruno A, Mulholland C, Kojima M, Esteban E. The development of illustrative examples for the establishment and application of microbiological criteria for foods and their role in international standard development. Food Control 2015. [DOI: 10.1016/j.foodcont.2015.06.043] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
33
|
Agámez Medina GL, González-Arévalo A, Gómez-Arnau JI, García del Valle S, Rubio JA, Esteban E, Pérez E. Effects of droperidol and ondansetron on dispersion of ventricular repolarization: A randomized double-blind clinical study in anesthetized adult patients. Rev Esp Anestesiol Reanim 2015; 62:495-501. [PMID: 25887095 DOI: 10.1016/j.redar.2015.01.017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/19/2014] [Revised: 01/28/2015] [Accepted: 01/29/2015] [Indexed: 06/04/2023]
Abstract
BACKGROUND AND OBJECTIVE Droperidol and ondansetron prolong QT interval, a circumstance that has raised some concerns regarding the possibility of inducing torsades de pointes (TdP). However drug-induced spatial dispersion of ventricular repolarization has been shown to be the principal arrhythmogenic substrate for TdP. The aim of this study is to explore the effects of droperidol and ondansetron on the dispersion of repolarization, measured using the T peak-to-end interval (Tp-e) and Tp-e/QT and Tp-e/RR(1/2) ratios in surgical anesthetized patients. METHODS A randomized, double-blind study carried out on sixty-three adult patients without cardiac disease or factors favoring QT prolongation and undergoing non-cardiac surgery were randomly assigned to the droperidol or ondansetron group. Under propofol anesthesia, a 12-lead EKG was obtained, and 1.25mg droperidol or 4mg ondansetron was injected. Five minutes later, a new 12-lead EKG was recorded. EKG analyses were independently performed by two cardiologists blinded to the state of the traces or group allocation. QT, RR and Tp-e intervals were measured by averaging five successive beats in leadII (QT) or V5 (Tp-e). The mean value for each measurement was calculated for statistical analysis. RESULTS Thirty-two patients (19 women) received droperidol, and 31 (22 women) ondansetron. Droperidol and ondansetron prolonged the QTcF interval (Fridericia formula) by 6.8 and 7.2ms (mean values) respectively, but neither droperidol nor ondansetron increased the Tp-e interval or Tp-e/QT and Tp-e/RR(1/2) ratios. CONCLUSION At antiemetic doses, neither ondansetron (4mg) nor droperidol (1.25mg) increases the dispersion of ventricular repolarization in healthy adult patients anesthetized with propofol.
Collapse
Affiliation(s)
- G L Agámez Medina
- Departamento de Anestesiología y Reanimación, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España.
| | - A González-Arévalo
- Departamento de Anestesiología y Reanimación, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España
| | - J I Gómez-Arnau
- Departamento de Anestesiología y Reanimación, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España
| | - S García del Valle
- Departamento de Anestesiología y Reanimación, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España
| | - J A Rubio
- Unidad de Cardiología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España
| | - E Esteban
- Unidad de Cardiología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España
| | - E Pérez
- Research Institute, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España
| |
Collapse
|
34
|
Angelergues A, Bellmunt J, Efstathiou E, Gonzalez I, Gyftaki R, Delanoy N, Ozguroglu M, Flechon A, Guillot A, Le Moulec S, Castellano D, Esteban E, Munarriz J, Campos Balea B, Ardavanis A, Stefanou D, Oudard S. 2538 Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31357-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
35
|
Grande E, Pinto A, Dur´n I, López-Criado P, Su´rez C, Gonz´lez-Larriba J, S´nchez-Lorenzo L, Maroto P, L´inez N, Gonz´lez del Alba A, S´ez M, Alonso-Gordoa T, Pérez-Valderrama B, Puente J, Morales R, Esteban E, Manneh R, Benedetti J, Carles-Galcerán J, Castellano D. 2540 Experience with radium-223 as a systemic treatment for patients (pts) with castration-resistant prostate cancer (CRPC) out of a clinical trial in Spain. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31359-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
36
|
Maroto P, Ruiz A, Esteban E, León L, Munarriz J, Su´rez C, Pinto A, Mellado B, Durán I, García-Carbonero I, Arranz J, Sala N, Fernández O, Lainez N, Peláez I, López A, Viqueira A. 2616 Efficacy and safety of Temsirolimus in patients with metastatic renal cell carcinoma: Final results from the Spanish experience. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31434-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
37
|
Oudard S, Angelergues A, Efstathiou E, Gonzalez I, Gyftaki R, Delanoy N, Ozguroglu M, Flechon A, Guillot A, Le Moulec S, Castellano D, Esteban E, Munarriz J, Campos Balea B, Ardavanis A, Stefanou D, Bellmunt J. 2541 Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31360-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
38
|
Esteban E, Majem M, Martinez Aguillo M, Martinez Banaclocha N, Dómine M, Gómez Aldaravi L, Juan O, Cajal R, Gonzalez Arenas M, Provencio M. Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study. Cancer Epidemiol 2015; 39:291-7. [DOI: 10.1016/j.canep.2015.02.003] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Revised: 02/13/2015] [Accepted: 02/18/2015] [Indexed: 10/23/2022]
|
39
|
Xu CF, Johnson T, Garcia-Donas J, Choueiri TK, Sternberg CN, Davis ID, Bing N, Deen KC, Xue Z, McCann L, Esteban E, Whittaker JC, Spraggs CF, Rodríguez-Antona C, Pandite LN, Motzer RJ. IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. Br J Cancer 2015; 112:1190-8. [PMID: 25695485 PMCID: PMC4385958 DOI: 10.1038/bjc.2015.64] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2014] [Revised: 01/15/2015] [Accepted: 01/27/2015] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND We evaluated germline single nucleotide polymorphisms (SNPs) for association with overall survival (OS) in pazopanib- or sunitinib-treated patients with advanced renal cell carcinoma (aRCC). METHODS The discovery analysis tested 27 SNPs within 13 genes from a phase III pazopanib trial (N=241, study 1). Suggestive associations were then pursued in two independent datasets: a phase III trial (COMPARZ) comparing pazopanib vs sunitinib (N=729, study 2) and an observational study of sunitinib-treated patients (N=89, study 3). RESULTS In study 1, four SNPs showed nominally significant association (P≤0.05) with OS; two of these SNPs (rs1126647, rs4073) in IL8 were associated (P≤0.05) with OS in study 2. Because rs1126647 and rs4073 were highly correlated, only rs1126647 was evaluated in study 3, which also showed association (P≤0.05). In the combined data, rs1126647 was associated with OS after conservative multiple-test adjustment (P=8.8 × 10(-5); variant vs reference allele hazard ratio 1.32, 95% confidence interval: 1.15-1.52), without evidence for heterogeneity of effects between studies or between pazopanib- and sunitinib-treated patients. CONCLUSIONS Variant alleles of IL8 polymorphisms are associated with poorer survival outcomes in pazopanib- or sunitinib-treated patients with aRCC. These findings provide insight in aRCC prognosis and may advance our thinking in development of new therapies.
Collapse
Affiliation(s)
- C-F Xu
- GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK
| | - T Johnson
- GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK
| | - J Garcia-Donas
- Department of Medical Oncology, Centro Integral Oncológico Clara Campal, Calle de Oña 10, Madrid 28050, Spain
- Spanish Oncology Genitourinary Group (SOGUG), Madrid, Spain
| | - T K Choueiri
- Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
| | - C N Sternberg
- Department of Medical Oncology, San Camillo and Forlanini Hospitals, Circonvallazione Gianicolense 87, Rome 00152, Italy
| | - I D Davis
- Monash University Eastern Health Clinical School, 5 Arnold Street, Victoria 3128, Australia
| | - N Bing
- GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
| | - K C Deen
- GlaxoSmithKline, 250 S. Collegeville Road, Collegeville, PA 19426-0989, USA
| | - Z Xue
- GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
| | - L McCann
- GlaxoSmithKline, 250 S. Collegeville Road, Collegeville, PA 19426-0989, USA
| | - E Esteban
- Department of Medical Oncology, Centro Integral Oncológico Clara Campal, Calle de Oña 10, Madrid 28050, Spain
- Hospital Universitario Central de Asturias, Calle Carretera de Rubín, Oviedo 33011, Spain
| | - J C Whittaker
- GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK
| | - C F Spraggs
- GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK
| | - C Rodríguez-Antona
- Spanish National Cancer Research Centre and ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Calle de Melchor Fernández Almagro 3, Madrid 28029, Spain
| | - L N Pandite
- GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA
| | - R J Motzer
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
| |
Collapse
|
40
|
Oudard S, Angelergues A, Maeso IG, Delanoy N, Flechon A, Özgüroğlu M, Castellano D, Guillot A, Le Moulec S, Esteban E, Munarriz J, Campos B, Bellmunt J. Prognostic Factors for Survival and Sequencing of Life-Extending Therapies in Metastatic Castration Resistant Prostate Cancer (Mcrpc) Patients (Pts) in Post-Docetaxel (D) Setting. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu336.37] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Maroto P, Lainez N, Esteban E, Espinosa M, Juan M, Etxaniz O, Suarez C, Sepúlveda J, Rubio G, Arija JA, Jimenez L, Saez M, Puente J, Gonzalez IC, Gallardo E, Jurado J, Garcia-Donas J, Brea ML, Garrido M, Otero DSDPY. Real Life Efficacy and Safety of Axitinib (Axi) in Patients with Renal Cell Carcinoma (Rcc): Results from the Spanish Compassionate Use Program. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu337.42] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Ferrer Puchol M, Lanciego C, Esteban E, Ciampi J, Edo M, Ferragud S. Embolización selectiva como tratamiento de la hemorragia obstétrica. Radiología 2014; 56:148-53. [DOI: 10.1016/j.rx.2012.01.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2011] [Revised: 01/15/2012] [Accepted: 01/19/2012] [Indexed: 10/28/2022]
|
43
|
Forletti A, Juliarena M, Ceriani C, Amadio A, Esteban E, Gutiérrez S. Identification of cattle carrying alleles associated with resistance and susceptibility to the Bovine Leukemia Virus progression by real-time PCR. Res Vet Sci 2013; 95:991-5. [DOI: 10.1016/j.rvsc.2013.07.018] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2012] [Revised: 07/14/2013] [Accepted: 07/16/2013] [Indexed: 10/26/2022]
|
44
|
Nuño de la Rosa I, Palmero J, Miralles J, Amorós A, Ferrer M, Esteban E. Treatment of hemorrhagic complications of percutaneous nephrolithotomy in Galdakao position. Actas Urol Esp 2013; 37:587-91. [PMID: 23411067 DOI: 10.1016/j.acuro.2012.11.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2012] [Accepted: 11/27/2012] [Indexed: 11/27/2022]
Abstract
OBJECTIVE Percutaneous Nephrolithotomy (PCNL) is a technique with good results for the treatment of kidney stones, however, bleeding complications derived can be serious if not diagnosed and treated effectively. The aim of this study is to assess bleeding complications resulting from PCNL in Galdakao position and therapeutic management. MATERIAL AND METHODS Retrospective-longitudinal study of 172 PCNL performed in La Ribera Hospital between January 2005 and December 2011, analyzing their bleeding complications and the treatment provided for resolution. RESULTS Had bleeding complications 20 patients (11.6%). The need for transfusion in this series was 8.1% and the most common cause of blood transfusion the presence of postoperative retroperitoneal (7.5%). There were 6 arterial injuries (3.5%), 5 of them successfully treated with angiography and arterial selective embolization. CONCLUSIONS The arterial injuries following PCNL are rare but can be serious. The possibility of an urgent arteriography and selective embolization to the diagnosis permits an effective and safe treatment of bleeding without risk to the affected renal unit.
Collapse
|
45
|
Sroczynski G, Lhachimi S, Esteban E, Danner M, Sandmann F, Stürzlinger H, Conrads-Frank A, Zsifkovits J, Rosian I, Schnell-Inderst P, Siebert U, Gerber-Grote A. Die 1. Kosten-Nutzen-Bewertung des IQWiG - Ergebnisse und Methodische Aspekte am Beispiel der Antidepressiva Bewertung. Gesundheitswesen 2013. [DOI: 10.1055/s-0033-1354039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
46
|
Garcia-Donas J, Leandro-García L, González del Alba A, Morente M, Alemany I, Esteban E, Arranz J, Climent M, Gallardo E, Castellano D, Bellmunt J, Mellado B, Puente J, Moreno F, Font A, Hernando S, Robledo M, Rodríguez-Antona C. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol 2013; 24:2409-14. [DOI: 10.1093/annonc/mdt219] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
|
47
|
Bellmunt J, De Piedra CL, Esteban E, Climent M, González B, Álvarez-Ossorio J, Gonzalez IC, Mellado B, Lara P, Alcaraz A. Bone Turnover Markers and Potential Correlation with Outcomes in Patients with Genitourinary Cancer (Renal and Bladder) and Bone Metastasis (Results of the Tugamo Study). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33373-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
48
|
Maroto P, Esteban E, Fernández-Parra E, Méndez-Vidal M, Domenech M, León L, Pérez-Valderrama B, Calderero V, Gracia JP, Algaba F. C-MYC as a New Predictive Biomarker for Sunitinib in Metastatic Renal Clear Cell Carcinoma. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33402-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
49
|
Castellano D, Aparicio LA, Esteban E, Velasco G, Perez Q, Sanchez A, Pérez-Valderrama B, Batista N. Cabazitaxel in Patients with Advanced CRPC after Docetaxel-Failure. Results of Expanded Program Access (EAP) in Spain: Safety and Efficacy. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33515-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
50
|
Ruiz L, Esteban E, León L, Pinto A, Suarez C, Duran I, Lainez N, Lopez A, Viqueira A, Maroto P. Efficacy and Safety of Temsirolimus in Patients with Metastatic Renal Cell Carcinoma: Results from the Spanish Experience. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33410-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|